Model drug response across every ancestry — before the trial, not after.
Most evidence on how genes shape drug response comes from people of European ancestry. Anukriti turns population structure into an auditable input, so ancestry-specific risk surfaces early in drug development instead of late, when it is expensive to fix.
AWS AIdeasTop 20 — selected from 10,000+ ideas across 115 countries
Drug-response evidence skews European. Everyone else inherits the risk.
Pharmacogenomics is the study of how a person’s genes shape their response to a drug. Because most of that evidence comes from European-ancestry populations, risk in African, East Asian, South Asian, and admixed American groups is underrepresented — and it tends to surface at the clinical-trial stage, where changes are costly.
For the gene CYP2C19, “poor metaboliser” status carries roughly a 5× difference in risk across ancestries.
How we make ancestry an auditable inputDeterministic first. AI explains second. Auditable throughout.
Anukriti’s authority is a deterministic engine: the same input always returns the same result, traceable to its evidence. A plain- language AI layer sits on top for people who aren’t geneticists — but it never overrides the engine.
- 01
Genotype in
A patient or cohort genotype, resolved against the five 1000 Genomes superpopulations — 2,504 real phase-3 samples.
- 03
Auditable output
A trial-ready result with provenance and a call status — plus a plain-language AI explanation layered on top. The engine decides; the AI never does.
Every call carries provenance from CPIC and PharmVar, and resolves to one of three honest states:
calledEvidence sufficient — a result is returned.cannot_callThe engine refuses rather than guess, and cites the rule.insufficient_dataNot enough signal to decide — stated plainly.
Change the ancestry. Watch the recommendation change.
The same drug, read against different genetic backgrounds. This is a deterministic, offline illustration of what population-aware interpretation surfaces — pick a workflow and a population.
- Gene
- CYP2C19
- Variant
- *2/*3
- Metaboliser status
- Poor metaboliser
- Population signal
- Poor-metaboliser prevalence is markedly higher in parts of East Asia.
InterpretationSubstantially reduced active metabolite — an alternative may be warranted.
Illustrative output for research and education only. Not patient data, and not medical advice.
Tested against a 5,700-patient warfarin cohort.
On the IWPC warfarin cohort, the engine’s predicted risk tiers line up with the doses patients were actually prescribed — a clean gradient from low to high. That is a consistency check, not an outcome: it shows the tiers track real prescribing, not that any patient was dosed wrongly. We make no claim about patient outcomes from this cohort.
- 5,700IWPC warfarin cohortPatients from the International Warfarin Pharmacogenetics Consortium used to test dosing across ancestries.IWPC · Klein et al., NEJM 2009
- 2,5041000 Genomes samplesReal phase-3 reference samples spanning all five superpopulations.1000 Genomes Project, phase 3
- 3Live PGx workflowsClopidogrel/CYP2C19, warfarin/CYP2C9+VKORC1, and simvastatin/SLCO1B1 — all CPIC level A.
- 5Superpopulations coveredAFR, EUR, EAS, SAS, AMR — every major ancestry in the output.
Open findingsA companion CPIC-table audit ships with open findings disclosed, including a CYP2C9 table mismatch our own audit found. We publish what doesn’t work yet, not only what does.
You can run the audit yourself.
panelaudit is public, Apache-2.0, and archived with a DOI. It answers one question, before any patient is sequenced: what a given genotyping panel gets wrong in a given population, and which position to add next. It computes from CPIC’s public allele definitions and frequencies. No patient data. No human samples. No sequence data.
Cost of transferring a European-optimal five-locus panel (misclassifications per 100,000 people)
- CYP2C19Oceanian27,133
- DPYDSub-Saharan African5,508
- CYP3A5Latino4,941
Pinned by the repository’s own CI. In 25 of the 33 gene–population pairs with any measurable cost, a population-optimal panel of the same size brings misclassification to exactly zero — so the residual error is removable using variants CPIC already publishes.
Audits seven genes
- DPYD
- TPMT
- NUDT15
- CYP2B6
- CYP2C19
- CYP2C9
- CYP3A5
Refuses eight more, by name
- CYP2D6
- Phenotype depends on copy number, which no set of rsIDs can express.
- G6PD
- X-linked.
- NAT2
- The engine’s table records a phenotype term in its function column.
- SLCO1B1, VKORC1, CYP1A2, CYP3A4
- The tables needed do not exist.
- UGT1A1
- Three alleles share one position and do not share a function, so a set of rsIDs cannot tell them apart.
Refusing by name beats producing a confidently wrong report.
Reproduce it
python -m panelaudit --gene DPYD --panel cpic4 --population "Central/South Asian"No third-party runtime dependencies.
Read this number carefullyA misclassification is a property of a panel, not a patient. These counts are not counts of clinical harm, and we do not present them as any.
Why population-aware PGx matters.
Published evidence shows genotype-frequency differences materially change drug safety and efficacy. Four examples, each with the population that carries the highest documented risk.
Clopidogrel
CYP2C19*2*3Poor metabolisers form too little active drug, weakening platelet inhibition and raising cardiovascular event risk.
Highest risk: EASPoor-metaboliser prevalence is markedly higher in parts of East Asia than in many European cohorts.
NCBI Medical Genetics Summary
Warfarin
CYP2C9 + VKORC1*2*3−1639G>ACombined variant status drives the correct weekly dose; getting it wrong risks bleeding or clotting.
Highest risk: AFRVKORC1 haplotype distribution diverges most from the European reference used by most dosing algorithms.
NIH/PMC population dosing study
Simvastatin
SLCO1B1*5 (c.521T>C)Reduced hepatic uptake raises plasma statin levels, increasing myopathy and rhabdomyolysis risk.
Highest risk: SAS*5 allele frequency is notably higher in South Asian populations (~16%) than in some others (~2%).
NCBI Medical Genetics Summary
Carbamazepine
HLA-B*15:02Carriers face sharply elevated risk of Stevens–Johnson Syndrome, a life-threatening skin reaction.
Highest risk: EASHLA-B*15:02 is strongly associated with severe reactions and clusters in several Asian cohorts.
FDA recommendation background
From research prototype to clinical-grade validation.
Five phases, staged honestly. The first three are complete and live; the fourth is new and early; the fifth is in progress.
- 01Completed · Live
Deterministic trial wedge
Three shipped workflows with auditable call statuses and CPIC + PharmVar provenance.
- Clopidogrel / CYP2C19
- Warfarin / CYP2C9 + VKORC1 + CYP4F2
- Simvastatin / SLCO1B1
- 02Completed · Live
Reviewer trust layer
Benchmarks, confidence calibration, reproducibility packs, evidence mapping, and reviewer reports.
- Evidence Sufficiency Layer with named refusals
- 12 R-rules · 10 V-rules · 9 U-rules
- 3 bias-detection kinds
- 03Completed · Live
Pilot operations
The production API and a public, zero-auth demo surface are running, with real 1000 Genomes sample mode.
- Production API on Azure Container Apps + MongoDB Atlas
- Deployed engine: anukriti-pgx-core 0.11.0, reported by the API itself
- Public zero-auth demo, 1000 Genomes sample mode
- Per-cohort outcome distributions
- Shareable run permalinks
- 04New · Early
Trial-planning surface
A cohort-level question for a trial sponsor: given the genetic architecture of two cohorts for one enzyme, at what fraction metabolised does a drug cross into a dosing liability. It takes no patient, no genotype and no VCF, and returns no dose.
- Trial-planning tool at /tools/fm-star, over four API routes
- Four named refusals: U-FM, U-PREV, U-CV, U-MODULE
- Of three audited probes, only S-warfarin (CYP2C9) passes the extraction audit
- Omeprazole and metoprolol therefore give upper bounds, not estimates
- Early work — not validated, and not offered as a clinical conclusion
- 05In progress
Clinical-grade validation
Deeper concordance benchmarking and an ancestry-specific evidence pack.
- PharmCAT concordance benchmark
- BCHE / Vysya founder-community wedge (Kerdoncuff 2025)
- CYP2D6 CNV calling via Cyrius
- Full AFR-specific evidence pack
- Partnership outreach: PharmVar, LASI-DAD, GenomeIndia
Recognised early. Built on the standards the field trusts.
Named an AWS AIdeas winner — one of 20 chosen from more than 10,000 ideas across 115 countries, and featured on the AWS Builder Center.
The AWS AIdeas program surfaces early-stage ideas building with AWS AI. Anukriti was recognised for its population-aware pharmacogenomics approach.
- 1000 Genomes
- ChEMBL
- RDKit
- CPIC
- PharmVar
See where population-aware PGx changes your decisions.
Anukriti is a research and education platform for exploring population-specific drug response — not a clinical diagnostic. If you’re weighing the science, the market, or a partnership, we’ll walk you through what’s live and what’s next.
- InvestorsA structural gap in a high-value market, with early validation.
- ProgramsA small team already shipping and validating real workflows.
- GrantsAuditable, reproducible, and built around health equity.